Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase Ⅰ Clinical Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years
NCT05003479 is registered in ClinicalTrials.gov with Shenzhen Kangtai Biological Products Co., LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase Ⅰ Clinical Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years
- Lead sponsor
- Shenzhen Kangtai Biological Products Co., LTD
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- August 31, 2021
- Completion date
- October 31, 2022
- Enrollment
- 84 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.